germline variants, and even the identification of genomic changes conferring acquired resistance to these therapies. Whole-genome and -exome sequencing studies of primary and metastatic tumors in different cancers have revealed intratumoral heterogeneity as a key driver of acquired resistance and clonal evolution (Jamal-Hanjani et al. 2017) . Furthermore, NGS technology has allowed us to identify alterations even in scarce biopsy tissues or in simple blood draws (liquid biopsy) for cases in which collecting tissue for molecular testing might be unsafe for the patient (Ignatiadis and Dawson 2014) . This special issue contains several such reports of the use of liquid biopsy for patient diagnosis or monitoringevidence that this approach is being used with increasing frequency in the clinical setting.
These advances in cancer genomics have paved the way for a new era of precision medicine in oncology-an era in which a patient's tumor can be characterized extensively for mutations and other molecular abnormalities, and treatment can be based on the identified molecular changes along with the cancer's tissue of origin. It is not a new concept, but the use of NGS, bioinformatics tools, and large-scale cancer variant databases have created an opportunity for significant onward movement of this approach.
In current clinical practice, providers encounter the growing challenge of interpreting variants for each patient, who may have one to 10 somatic mutations involving 50 to 500 genes. Furthermore, the types of mutations that can be detected continue to expand. The BRAF oncogene provides an illustration of this challenge. This oncogene may contain mutations that either lead to kinase activation (Class I and II point mutations), kinase-dead activity (Class III point mutations), kinase domain duplication, or may be involved in a gene fusion. Each of these classes of mutations may be responsive to a RAF inhibitor, MEK inhibitor, or combination therapy depending on the biology it determines. However, sifting through these mutations, biological evidence, and potential matching therapies is a time-consuming and arduous task that lacks harmonization and guidelines. This complex process, called variant prioritization, is aided by large publicly accessible databases like CIViC (Griffith et al. 2017) , the GA4GH VICC (Wagner et al. 2018) , or OncoKB/cBioPortal (Chakravarty et al. 2017) , among others. These resources have been designed as a translational bridge between researchers and clinicians, to lower the barriers of access and make comprehensible the individual genes and their alterations with functional and/or drug therapy responses. However, because the reality is that functional consequences are known for only a small fraction of the many variants identified by NGS, increasingly there are decision-support tools emerging to facilitate the interpretation of cancer genomes in this context. Two of the case reports in this issue highlight how such tools can be utilized in cancer precision medicine.
Each incremental advance in cancer knowledge is ultimately an improvement in patient care. Although the scientific value of NGS-based advancements is undoubtedly critical, the derived clinical benefits are still being discussed. Nevertheless, NGS is driving the field of translational precision cancer medicine at a rapid pace, coupled with increasing evidence from patient-based studies and ensuing therapeutic management strategies. This issue of Cold Spring Harbor Molecular Case Studies provides insights into the current state and clinical practice of precision oncology, the challenges that we currently face, and the enormous opportunities to come. These contributed manuscripts provide a glimpse into our understanding of novel genomic features such as druggable fusions, new analytical approaches, the complexity of data generated, and how to interpret these complex data in the context of patient care.
We are thankful to the many groups and individuals who contributed their work and points of view to this issue, and also to the patients who consented to have their stories told in order to benefit all future patients. We hope that you will find these contributions enlightening regarding the current status of precision oncology and inspirational of what is to come.
